German immunotherapy biotech BioNTech files for a $100 million US IPO
BioNTech, a German biotech developing individualized immunotherapies for cancer, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The Mainz, Germany-based company was founded in 2008 and booked $150 million in revenue for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol BNTX. BioNTech filed confidentially on June 19, 2019. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank, and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.
The article German immunotherapy biotech BioNTech files for a $100 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.